Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ian P. Naya"'
Autor:
François Maltais, Leif Bjermer, Edward M. Kerwin, Paul W. Jones, Michael L. Watkins, Lee Tombs, Ian P. Naya, Isabelle H. Boucot, David A. Lipson, Chris Compton, Mitra Vahdati-Bolouri, Claus F. Vogelmeier
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-15 (2019)
Abstract Background Prospective evidence is lacking regarding incremental benefits of long-acting dual- versus mono-bronchodilation in improving symptoms and preventing short-term disease worsening/treatment failure in low exacerbation risk patients
Externí odkaz:
https://doaj.org/article/4397ec211a684a41994894718e1f28f9
Autor:
MeiLan K. Han, Gerard J. Criner, Mark T. Dransfield, David M.G. Halpin, Christine E. Jones, Sally Kilbride, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Neil Martin, Fernando J. Martinez, Robert A. Wise, Ian P. Naya, Dave Singh
Publikováno v:
ERJ Open Research, Vol 7, Iss 1 (2021)
Introduction Clinically important deterioration (CID) is a multicomponent measure for assessing disease worsening in chronic obstructive pulmonary disease (COPD). This analysis investigated the prognostic value of a CID event on future clinical outco
Externí odkaz:
https://doaj.org/article/31387cf5c65f4a33bbf91b30a4accb67
Autor:
Claus F. Vogelmeier, Edward M. Kerwin, Leif H. Bjermer, Lee Tombs, Paul W. Jones, Isabelle H. Boucot, Ian P. Naya, David A. Lipson, Chris Compton, Neil Barnes, François Maltais
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Rationale: Symptom relief is a key treatment goal in patients with chronic obstructive pulmonary disease (COPD). However, there are limited data available on the response to bronchodilator therapy in patients at low risk of exacerbations with differe
Externí odkaz:
https://doaj.org/article/864c880f44ca4df1a9f0961dff369d9a
Publikováno v:
Respiratory Research, Vol 19, Iss 1, Pp 1-10 (2018)
Abstract Background Chronic obstructive pulmonary disease (COPD) is characterized by varying trajectories of decline. Information regarding the prognostic value of preventing short-term clinically important deterioration (CID) in lung function, healt
Externí odkaz:
https://doaj.org/article/c20db8867d694d68b3b6e6f6ec589d54
Autor:
François Maltais, Claus F. Vogelmeier, Edward M. Kerwin, Leif H. Bjermer, Paul W. Jones, Isabelle H. Boucot, David A. Lipson, Lee Tombs, Chris Compton, Ian P. Naya
Publikováno v:
Respiratory medicine. 200
Early MAXimisation of bronchodilation for improving COPD stability (EMAX) was a large, multicentre, multi-national, randomised, double-blind, 24-week trial. EMAX evaluated the efficacy and safety of dual bronchodilator therapy with umeclidinium bromi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c217274765fd686994a330031cd522e0
https://pubmed.ncbi.nlm.nih.gov/35803172
https://pubmed.ncbi.nlm.nih.gov/35803172
Publikováno v:
Advances in Therapy
Introduction Assessing clinically important measures of disease progression is essential for evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease (COPD). This analysis assessed whether providing additional bron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c7278af2b307f98f6c9364d647f7f8c9
https://pubmed.ncbi.nlm.nih.gov/30191464
https://pubmed.ncbi.nlm.nih.gov/30191464
Autor:
Edward M Kerwin, Isabelle H Boucot, Claus F Vogelmeier, Francois Maltais, Ian P Naya, Lee Tombs, Paul W Jones, David A Lipson, Tom Keeley, Leif Bjermer
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 14 (2020)
Background: In chronic obstructive pulmonary disease (COPD), both the time needed for patients to gain symptom improvement with long-acting bronchodilator therapy and whether an early response is predictive of a sustained response is unknown. This st
Externí odkaz:
https://doaj.org/article/2846b6af6f334253a8cde4194fb58760